IDOV-Immune Trial
Phase 1
78
about 1.8 years
18+
3 sites in MO, TX
What this study is about
This trial is testing IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. The goal is to determine the safety and best dose of this treatment by monitoring side effects and how it affects the body and immune system. Participants will receive a single IV infusion of IDOV-Immune and be closely monitored.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive IDOV-Immune (oncolytic vaccinia virus)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
intravenous
Primary: Determination of the Maximum Tolerated Dose (MTD), Incidence of Dose-Limiting Toxicities (DLTs), Safety and Tolerability of IDOV-Immune by Dose Level
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Objective Response Rate (ORR), Overall Survival (OS), Pharmacodynamic and Biomarker Responses Following IDOV-Immune Administration, Pharmacokinetic Parameters of IDOV-Immune by Dose Level, Progression-Free Survival (PFS)
Endocrinology, Oncology